Skip to main content

Table 3 Clinical outcomes during the course of anticoagulant therapy

From: Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

  Pulmonary embolism Deep vein thrombosis Rate ratio
(95%CI)
N Events per 100
patient-years
N Events per 100
patient-years
Patients, N 14 9   
 Recurrent PE 0 0
 Recurrent DVT 0 1 16.67 (0. 22-92.72)
 Major bleeding 1 10.02 (0. 13-55.75) 1 16.67 (0. 22-92.72) 0.60 (0.04–9.61)
Site of major bleeding (days) a ,
 Epistaxis (32b) 0 1 16.67 (0. 22-92.72)
 GI (534) 1 10.02 (0. 13-55.75) 0
 Non-major bleeding 3 30.06 (6.04–87.83) 3 50 (10.05–146.1) 0.60 (0. 12-2.98)
Site of minor bleeding (days) a ,
 Epistaxis (9,31,179) 3 30.06 (6.04–87.83) 0
 Others (0b,5,50) 0 3 50 (10.05–146.1)
Death 1 10.02 (0. 13-55.75) 0
Causes of death,
 Respiratory insufficiency 1 10.02 (0. 13-55.75) 0
  1. Abbreviations: PE pulmonary embolism, DVT deep vein thrombosis; 95%CI, 95% confidence intervals, GI gastrointestinal
  2. a Days from index VTE diagnosis to bleeding event
  3. b Receiving LMWH < 100 IU/kg/day